VTVT News | Roxom Stocks

1 BTC

=

- USD

Loading market data...

VT

Mkt Cap

$104.9M

Volume

11.41K

Next Earnings

November 5th

Chart Financials Earnings News About Insider Filings

iOnctura appoints Paul Sekhri as Chair of its Board of DirectorsiOnctura, a clinical-stage precision oncology company, announced the appointment of Paul Sekhri as Chair of its Board of Directors. Sekhri brings over 35 years of life science executive experience and has led multiple biotech companies through commercialization. The appointment comes as iOnctura prepares for late-stage development of roginolisib, its lead PI3Kδ inhibitor candidate, with two randomized Phase II studies fully enrolled. Roginolisib has shown promising clinical signals including doubled overall survival in uveal melanoma compared to historical controls.GlobeNewswire Inc. · Oct 15, 2026

vTv Therapeutics to Participate in September Investor ConferencesvTv Therapeutics announced that management will participate in two investor conferences in September 2026: the H.C. Wainwright 28th Annual Global Investment Conference on September 16 and the 5th Annual ROTH Healthcare Opportunities Conference on September 29. The company continues advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes, with its Phase 3 CATT1 trial expected to complete enrollment in Q3 2026.GlobeNewswire Inc. · Sep 2, 2026

vTv Therapeutics Announces New Appointments to its Scientific Advisory BoardvTv Therapeutics appointed a Scientific Advisory Board of distinguished clinicians and scientists to provide strategic guidance on cadisegliatin, a potential oral treatment for type 1 diabetes currently in Phase 3 clinical trials.GlobeNewswire Inc. · Oct 9, 2025

vTv Therapeutics Announces USPTO Allowance of Patent Covering CadisegliatinvTv Therapeutics received a USPTO patent for crystalline forms of cadisegliatin, a potential oral treatment for Type 1 diabetes, with patent protection extending through 2041.GlobeNewswire Inc. · Aug 11, 2025

vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Financial Officer as Company Reinitiates Phase 3 Trial of Oral T1D Adjunctive Therapy to InsulinvTv Therapeutics has appointed Michael Tung as its new Chief Financial Officer. The company has also reinitiated screening in its CATT1 Phase 3 trial for cadisegliatin, a potential first-in-class oral adjunctive therapy to insulin for the treatment of type 1 diabetes.GlobeNewswire Inc. · May 19, 2025

7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - Synergistic Rise of Pumps, CGMs, and Ultra-rapid-acting Insulins in T1D ManagementThe type 1 diabetes (T1D) market is expected to grow at a strong CAGR of 13.3% from 2023 to 2033, reaching $9.91 billion. Key drivers include the increased use of rapid-acting insulins, insulin pumps, and immunomodulatory therapies, as well as the rising global prevalence of T1D. However, high prices, patent expiries, and the failure of disease-modifying therapies in clinical trials pose challenges to market growth.GlobeNewswire Inc. · Jan 17, 2025

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 DiabetesCadisegliatin is a potential first-in-class oral liver selective glucokinase activator for T1D, which has been granted Breakthrough Therapy designation by the FDA for T1DGlobeNewswire Inc. · Jun 24, 2024

vTv Therapeutics Announces 2024 First Quarter Financial Results and Provides Corporate UpdateHIGH POINT, N.C., May 09, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter ended March 31, 2024, and provided an update on recent corporate developments.GlobeNewswire Inc. · May 9, 2024

vTv Therapeutics to Participate at the TD Cowen 44th Annual Healthcare ConferenceHIGH POINT, N.C., March 01, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today announced that Company management will be presenting at the TD Cowen 44th Annual Healthcare Conference, being held March 4-6, 2024, in Boston, MA. The presentation is scheduled for Tuesday, March 5, 2024, at 9:50 AM ET.GlobeNewswire Inc. · Mar 1, 2024

S&P 500 Edges Lower; ADT Posts Upbeat EarningsU.S. stocks traded lower toward the end of trading, with the Dow Jones index falling around 100 points on Wednesday. The Dow traded down 0.27% to 38,867.91 while the NASDAQ fell 0.50% to 15,954.75. The S&P 500 also fell, dropping, 0.18% to 5,068.92. Check This Out: Robinhood, Shake Shack And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Real estate shares rose by 1.4% on Wednesday. In trading on Wednesday, communication services shares fell by 0.8%. Top Headline ADT Inc. (NYSE: ADT) reported better-than-expected earnings for its fourth quarter on Wednesday. ADT posted fourth-quarter fiscal 2023 sales decline of 7.2% year-on-year to $1.22 billion, missing the consensus of $1.44 billion. Adjusted EPS was 25 cents, beating the consensus of 4 cents. ADT expects CSB segment revenue of 4.8 billion-$5.0 billion. The company expects adjusted EPS of $0.60 – $0.70, against consensus of $0.50. Equities Trading UP Vivani Medical, Inc. (NASDAQ: VANI) shares shot up 274% to $3.78 after the company announced preclinical data on weight loss effects for NPM-115 and disclosed that semaglutide is the active pharmaceutical ingredient in NPM-139. Shares of Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) got a boost, surging 159% to $2.1917. ...Benzinga · Feb 28, 2024

VT

VTVTvTv Therapeutics Inc. Class A Common Stock

VTVT

Pay with—

Available Balance0.00

Your PositionYou don't own any VTVT yet.

Related Tickers

Earnings